The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Palbociclib Overview

Reviewed: April 10, 2013
Updated: January 21, 2014

Palbociclib is an investigational drug currently being evaluated for the treatment of breast cancer. Palbociclib is an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6. It may work by inhibiting cell growth and DNA replication.

Palbociclib has received Breakthrough Therapy designation by the United States Food and Drug Administration (FDA) for the potential treatment of patients with breast cancer.

Pfizer has initiated a randomized, multi-center, double-blind Phase 3 study (known as Study 1008) evaluating palbociclib in combination with letrozole versus letrozole alone as a first-line treatment for post-menopausal patients with ER+, HER2- locally advanced or metastatic breast cancer.

In addition to breast cancer, palbociclib is being investigated for the treatment of other cancers.

Reviewed:  April 10, 2013
Updated:  January 21, 2014


Sign up for

My RxWiki  &   RxWiki Notify

Follow the medications that matter most to
you and Ask related questions.

Receive email notifications as soon as your
medication pages are updated.